309 related articles for article (PubMed ID: 29198914)
1. Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma.
Cosset É; Ilmjärv S; Dutoit V; Elliott K; von Schalscha T; Camargo MF; Reiss A; Moroishi T; Seguin L; Gomez G; Moo JS; Preynat-Seauve O; Krause KH; Chneiweiss H; Sarkaria JN; Guan KL; Dietrich PY; Weis SM; Mischel PS; Cheresh DA
Cancer Cell; 2017 Dec; 32(6):856-868.e5. PubMed ID: 29198914
[TBL] [Abstract][Full Text] [Related]
2. A role for GLUT3 in glioblastoma cell invasion that is not recapitulated by GLUT1.
Libby CJ; Gc S; Benavides GA; Fisher JL; Williford SE; Zhang S; Tran AN; Gordon ER; Jones AB; Tuy K; Flavahan W; Gordillo J; Long A; Cooper SJ; Lasseigne BN; Augelli-Szafran CE; Darley-Usmar V; Hjelmeland AB
Cell Adh Migr; 2021 Dec; 15(1):101-115. PubMed ID: 33843470
[TBL] [Abstract][Full Text] [Related]
3. Novel Integrin αvβ3-Specific Ligand for the Sensitive Diagnosis of Glioblastoma.
Zhang L; Shan X; Meng X; Gu T; Guo L; An X; Jiang Q; Ge H; Ning X
Mol Pharm; 2019 Sep; 16(9):3977-3984. PubMed ID: 31306580
[TBL] [Abstract][Full Text] [Related]
4. Glut3 Addiction: A Druggable Vulnerability in Glioblastoma.
Bunda S; Zadeh G; Aldape KD
Cancer Cell; 2017 Dec; 32(6):726-727. PubMed ID: 29232550
[TBL] [Abstract][Full Text] [Related]
5. miR-3189-targeted GLUT3 repression by HDAC2 knockdown inhibits glioblastoma tumorigenesis through regulating glucose metabolism and proliferation.
Kwak S; Park SH; Kim SH; Sung GJ; Song JH; Jeong JH; Kim H; Ha CH; Kim SW; Choi KC
J Exp Clin Cancer Res; 2022 Mar; 41(1):87. PubMed ID: 35260183
[TBL] [Abstract][Full Text] [Related]
6. Downregulated CLIP3 induces radioresistance by enhancing stemness and glycolytic flux in glioblastoma.
Kang H; Lee S; Kim K; Jeon J; Kang SG; Youn H; Kim HY; Youn B
J Exp Clin Cancer Res; 2021 Sep; 40(1):282. PubMed ID: 34488821
[TBL] [Abstract][Full Text] [Related]
7. A Key Role of DNA Damage-Inducible Transcript 4 (DDIT4) Connects Autophagy and GLUT3-Mediated Stemness To Desensitize Temozolomide Efficacy in Glioblastomas.
Ho KH; Chen PH; Chou CM; Shih CM; Lee YT; Cheng CH; Chen KC
Neurotherapeutics; 2020 Jul; 17(3):1212-1227. PubMed ID: 31916238
[TBL] [Abstract][Full Text] [Related]
8. Metastatic Colorectal Cancer Rewrites Metabolic Program Through a Glut3-YAP-dependent Signaling Circuit.
Kuo CC; Ling HH; Chiang MC; Chung CH; Lee WY; Chu CY; Wu YC; Chen CH; Lai YW; Tsai IL; Cheng CH; Lin CW
Theranostics; 2019; 9(9):2526-2540. PubMed ID: 31131051
[No Abstract] [Full Text] [Related]
9. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
10. αVβ3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4.
Jin ZH; Furukawa T; Degardin M; Sugyo A; Tsuji AB; Yamasaki T; Kawamura K; Fujibayashi Y; Zhang MR; Boturyn D; Dumy P; Saga T
Mol Cancer Ther; 2016 Sep; 15(9):2076-85. PubMed ID: 27422811
[TBL] [Abstract][Full Text] [Related]
11. EGFR Activates a TAZ-Driven Oncogenic Program in Glioblastoma.
Gao M; Fu Y; Zhou W; Gui G; Lal B; Li Y; Xia S; Ji H; Eberhart CG; Laterra J; Ying M
Cancer Res; 2021 Jul; 81(13):3580-3592. PubMed ID: 33910930
[TBL] [Abstract][Full Text] [Related]
12. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor gamma as a theragnostic target for mesenchymal-type glioblastoma patients.
Hua TNM; Oh J; Kim S; Antonio JM; Vo VTA; Om J; Choi JW; Kim JY; Jung CW; Park MJ; Jeong Y
Exp Mol Med; 2020 Apr; 52(4):629-642. PubMed ID: 32280134
[TBL] [Abstract][Full Text] [Related]
14. Glioblastomas require integrin αvβ3/PAK4 signaling to escape senescence.
Franovic A; Elliott KC; Seguin L; Camargo MF; Weis SM; Cheresh DA
Cancer Res; 2015 Nov; 75(21):4466-73. PubMed ID: 26297735
[TBL] [Abstract][Full Text] [Related]
15. Integrin control of the transforming growth factor-β pathway in glioblastoma.
Roth P; Silginer M; Goodman SL; Hasenbach K; Thies S; Maurer G; Schraml P; Tabatabai G; Moch H; Tritschler I; Weller M
Brain; 2013 Feb; 136(Pt 2):564-76. PubMed ID: 23378223
[TBL] [Abstract][Full Text] [Related]
16. EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis.
Liu Z; Han L; Dong Y; Tan Y; Li Y; Zhao M; Xie H; Ju H; Wang H; Zhao Y; Zheng Q; Wang Q; Su J; Fang C; Fu S; Jiang T; Liu J; Li X; Kang C; Ren H
Oncotarget; 2016 Jan; 7(4):4680-94. PubMed ID: 26717039
[TBL] [Abstract][Full Text] [Related]
17. Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells.
Kim KH; Seol HJ; Kim EH; Rheey J; Jin HJ; Lee Y; Joo KM; Lee J; Nam DH
Neuro Oncol; 2013 Feb; 15(2):161-71. PubMed ID: 23258844
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of a small-molecule inhibitor of Wnt signaling in glioblastoma cells.
De Robertis A; Valensin S; Rossi M; Tunici P; Verani M; De Rosa A; Giordano C; Varrone M; Nencini A; Pratelli C; Benicchi T; Bakker A; Hill J; Sangthongpitag K; Pendharkar V; Liu B; Ng FM; Then SW; Jing Tai S; Cheong SM; He X; Caricasole A; Salerno M
Mol Cancer Ther; 2013 Jul; 12(7):1180-9. PubMed ID: 23619303
[TBL] [Abstract][Full Text] [Related]
19. miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma.
Li Y; Liu Y; Ren J; Deng S; Yi G; Guo M; Shu S; Zhao L; Peng Y; Qi S
J Neurooncol; 2018 Jul; 138(3):499-508. PubMed ID: 29876787
[TBL] [Abstract][Full Text] [Related]
20. VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties.
Arif T; Krelin Y; Nakdimon I; Benharroch D; Paul A; Dadon-Klein D; Shoshan-Barmatz V
Neuro Oncol; 2017 Jul; 19(7):951-964. PubMed ID: 28339833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
